Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2025-006
    NCT ID
    • NCT06423911
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase III
    Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug
    • Phase III
    Principal Investigator
    • Jay
      Yang, M.D.

      Oncology - Hematology, Oncology - Medical View Profile

    Objective:

    Part A

    Primary Objective:

    • To compare the MMR rate at 24 weeks for olverembatinib versus bosutinib

    Secondary Objectives:

    • To compare the MMR rate at 96 weeks for olverembatinib versus bosutinib
    • To compare additional parameters of the efficacy of olverembatinib versus bosutinib
    • To compare the safety profile of olverembatinib versus bosutinib
    • To characterize the Population PK of olverembatinib in the CML-CP population
    • To evaluate Patient-Reported Outcome (PRO) measures of olverembatinib
    • To evaluate Health Economics Outcomes Research (HEOR) measures of olverembatinib

    Part B

    Primary Objective:

    • To evaluate the MMR rate by 24 weeks of olverembatinib in CML-CP patients with T315I mutation

    Secondary Objectives:

    • To evaluate the MMR rate by 96 weeks of olverembatinib in CML-CP patients with T315I mutation
    • To compare additional parameters of the efficacy of olverembatinib in CML-CP patients with T315I mutation
    • To evaluate the safety profile of olverembatinib in CML-CP patients with T315I mutation
    • To characterize the population PK of olverembatinib in the CML-CP population with T315I mutation
    • To evaluate PRO measures of olverembatinib
    • To evaluate HEOR measures of olverembatinib
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions